Provider Briefing: Cefepime Shortage in 2026
The Cefepime shortage continues to impact hospitals, infusion centers, and outpatient parenteral antibiotic therapy (OPAT) programs across the country. As a prescriber, you need to stay current on supply dynamics, available alternatives, and the resources that can help your patients maintain continuity of care.
This briefing summarizes what you need to know heading into 2026 — from the shortage timeline to practical prescribing strategies.
Shortage Timeline and Current Status
Cefepime injection has been subject to recurring shortages over the past decade, with notable disruptions in 2015-2016, 2019-2020, and the current shortage that began in approximately 2023.
As of early 2026:
- ASHP status: Cefepime injection is listed as a current shortage on the ASHP Drug Shortages database.
- BBraun has Cefepime on shortage due to ongoing manufacturing delays.
- Other manufacturers (Apotex, Sagent, Hospira/Pfizer, Baxter, Eugia/Dr. Reddy's) have experienced intermittent supply disruptions throughout 2024-2025, with variable recovery.
- Affected formulations: 500 mg, 1 g, and 2 g vials as well as pre-mixed IV bags (1 g/50 mL and 2 g/100 mL) are all subject to limited availability, though the specific presentation affected changes regularly.
The shortage is driven by the convergence of sterile manufacturing complexity, a thin manufacturer base for generic injectables, overseas API (active pharmaceutical ingredient) sourcing vulnerabilities, and sustained demand growth for empiric broad-spectrum IV coverage.
Prescribing Implications
The ongoing shortage requires prescribers to adopt flexible empiric and directed therapy approaches:
Empiric Therapy Adjustments
- Febrile neutropenia: ASCO/IDSA guidelines list Cefepime, Meropenem, Imipenem/Cilastatin, and Piperacillin/Tazobactam as acceptable monotherapy options. When Cefepime is unavailable, Piperacillin/Tazobactam 4.5 g IV every 6 hours is the most common substitution.
- Hospital-acquired pneumonia: Ceftazidime or Piperacillin/Tazobactam can replace Cefepime in anti-pseudomonal regimens. IDSA/ATS guidelines support these alternatives.
- Complicated UTIs / pyelonephritis: For AmpC-producing Enterobacterales (where Cefepime has a specific guideline niche), Meropenem is the preferred alternative. For non-AmpC pathogens, Ceftriaxone or Piperacillin/Tazobactam may suffice.
- Complicated intra-abdominal infections: Piperacillin/Tazobactam monotherapy or Meropenem can replace Cefepime + Metronidazole.
Directed Therapy Considerations
- Review culture and sensitivity data carefully. If Cefepime-susceptible options are limited, Meropenem is usually the safest escalation.
- For Pseudomonas-specific coverage, verify susceptibility to Ceftazidime or Piperacillin/Tazobactam before switching.
- Cefepime MIC breakpoints matter: for organisms with MICs at the upper end of susceptibility (8-16 mcg/mL), extended infusions (3-4 hours) improve pharmacodynamic target attainment, but only if Cefepime is available in sufficient quantities.
Dose Optimization When Supply Is Limited
Antimicrobial stewardship teams should consider:
- IV-to-oral stepdown as early as clinically appropriate (e.g., to Ciprofloxacin or Levofloxacin for appropriate urinary or respiratory infections)
- Extended infusion protocols (3-4 hour infusions of 2 g every 8 hours) to maximize pharmacodynamic exposure with limited supply, if the infection allows
- Restricted formulary use — reserving Cefepime for cases where alternatives are clearly inferior (e.g., AmpC-producing organisms, specific Pseudomonas susceptibility patterns)
Current Availability Picture
Hospital pharmacies should maintain active contact with multiple wholesalers and consider:
- Checking for availability across different vial sizes (1 g vs. 2 g) and formulations (powder vs. pre-mixed)
- Registering for manufacturer allocation programs
- Monitoring FDA Drug Shortages page and ASHP shortage database for updates
- Using Medfinder for Providers to check real-time availability data across pharmacies and distributors
Cost and Access for Patients
For inpatient care, Cefepime costs are typically absorbed within facility charges. For OPAT patients, key considerations include:
- Cash price: Approximately $363 for nine 2 g vials without insurance; as low as $93 with discount coupons
- Insurance coverage: Most commercial and Medicare plans cover generic Cefepime injection, though specialty pharmacy dispensing may require prior authorization
- No manufacturer savings programs: Maxipime brand is discontinued; no copay cards exist for generic Cefepime
- Patient assistance: NeedyMeds, RxAssist, and hospital charity care programs may help uninsured or underinsured patients
For cost-saving strategies to share with patients, see How to Save Money on Cefepime in 2026. For a provider-focused cost guide, see How to Help Patients Save Money on Cefepime.
Tools and Resources
Looking Ahead
Two developments may improve the landscape:
- Cefepime/Taniborbactam — a novel combination showing strong Phase 3 data for complicated UTIs, including carbapenem-resistant infections. If approved, this could provide a new treatment pathway and potentially a more stable supply chain.
- Cefepime/Enmetazobactam — another combination that extends Cefepime's activity against ESBL-producing organisms.
Both products could expand the Cefepime market and incentivize additional manufacturing investment, though neither fully addresses the immediate supply shortage of standalone Cefepime injection.
Final Thoughts
The Cefepime shortage requires proactive antimicrobial stewardship, flexible prescribing, and effective communication with patients and pharmacies. Use the tools available — especially Medfinder for Providers — to stay ahead of supply disruptions and ensure your patients receive appropriate, timely antibiotic therapy.
For a practical workflow guide, see How to Help Your Patients Find Cefepime in Stock.
%2C%20Color%3DOriginal.png)
